Development of asolectin-based liposomal formulation for controlled and targeted delivery of erlotinib as a model drug for EGFR monotherapy.

Pardeshi, Snehal; Tiwari, Amrendra; Titame, Uday; Singh, Pankaj K; Yadav, Pavan Kumar; Chourasia, Manish K

Pardeshi, Snehal; Tiwari, Amrendra; Titame, Uday; Singh, Pankaj K; Yadav, Pavan Kumar; Chourasia, Manish K.

Afiliação

Pardeshi S; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.
Tiwari A; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.
Titame U; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.
Singh PK; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.
Yadav PK; Department of Pharmaceutics, NIPER Hyderabad, Hyderabad, India.
Chourasia MK; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India.

J Liposome Res ; 32(4): 386-395, 2022 Dec.

Article em En | MEDLINE | ID: mdl-35225132

Assuntos

Lipossomos; Neoplasias Pancreáticas; Humanos; Cloridrato de Erlotinib/farmacologia; Linhagem Celular Tumoral; Receptores ErbB/metabolismo; Inibidores de Proteínas Quinases/farmacologia; Neoplasias Pancreáticas

Palavras-chave

Asolectin-erlotinib liposomes; epidermal growth factor receptor; pancreatic cancer; targeted delivery

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Lipossomos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Lipossomos Idioma: En Ano de publicação: 2022 Tipo de documento: Article